Drug Database
Back to search

Poland· PL-100391598

Gefitinib Synthon

A gefitinib product containing gefitinibum, registered in Poland by Synthon B.V.. The same ATC class is registered in 2 of our 19 countries.

ATC L01XE02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGefitinib SynthonATCL01XE02REGISTER NO.PL-100391598PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about gefitinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Gefitinib is registered in 2 of 19 countries.

Countries holding a registration under ATC L01XE02 (gefitinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 1 of them publish a price we can compare per daily dose
Search gefitinib products by name

Gefitinib · ATC L01XE02

2 / 19 countries

  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Gefitinibum
Manufacturer
Synthon B.V.
Country
Poland (PL)
ATC code
L01XE02
ATC class
Gefitinib
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991385637
  • gtin
    05909991385644

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

414 interactions on record for gefitinib.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check gefitinib against other medicinesHow interaction checks work

Gefitinib · interactions on record

414 records

  • 11 severe
  • 193 moderate
  • 5 minor
  • 205 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gefitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gefitinib products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Gefitinib Accord
  • Belgium · Gefitinib Accord, Gefitinib Sandoz
  • Bulgaria · Фромпо
  • Cyprus · Refetib
  • Czechia · Gefitinib Accord
  • Germany · Gefitinib Accord, Gefitinib Genthon
  • Denmark · Gefitinib Accord, Gefitinib Stada
  • Estonia · Gefitinib Auxilia, Gefitinib Norameda
  • Spain · Gefitinib Efg Genthon, Gefitinib Eugia
  • Finland · Gefitinib Accord, Gefitinib Stada
  • France · Gefitinib Arrow, Gefitinib Biogaran
  • United Kingdom (Northern Ireland) · Gefitinib Accord, Gefitinib Eugia (Uk)
  • Greece · Gefitinib Faran, Gefitinib Genepharm
  • Croatia · Gefitinib Pliva, Gefitinib Sandoz
  • Hungary · Gefitinib Genepharm, Gefitinib Onkogen
  • Iceland · Gefitinib Stada, Gefitinib Wh
  • Italy · Gefitinib Medac
  • Liechtenstein · Iressa
  • Lithuania · Gefitinib Norameda
  • Latvia · Gefitinib Norameda
  • Malta · Gefitinib Eugia, Gefitinib Genthon
  • Netherlands · Gefitinib Eugia, Gefitinib Genthon
  • Norway · Gefitinib Stada, Iressa
  • Portugal · Gefitinib Accord, Gefitinib Eugia
  • Romania · Gefitinib Accord, Gefitinib Polisano
  • Sweden · Gefitinib Accord, Gefitinib Stada
  • Slovenia · Phrompo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bcbab307-b4e0-4c71-9d6f-fb5ddd246023
GET /v1/drugs/bcbab307-b4e0-4c71-9d6f-fb5ddd246023?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909991385637 ¦ Rpz ¦ 129942\n30 tabl. w blistrze perforowanym\n05909991385644 ¦ Rpz ¦ 129943\n30 tabl. w blistrze",
  "substance": "Gefitinibum 250 mg",
  "common_name": "Gefitinibum",
  "pl_product_id": "100391598",
  "pozwolenie_nr": "25024",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about gefitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console